Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsProvidence Botulinum Toxin Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentProvidence Health PlanPolicy ORPTCNEU030.0826

    Botulinum Toxin Prior Authorization Policy - Medicare Part B

    Customize your policy alerts

    Sign up for Providence Health Plan Policy ORPTCNEU030.0826 alerts

    Get alerted when Policy ORPTCNEU030.0826 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity, coverage, coding, and prior authorization for botulinum toxin products and related procedures under Medicare Part B. It applies to Providence entities and providers requesting coverage for FDA-approved and certain evaluated off-label indications.

    Policy Summary
    PayerProvidence Health Plan
    PolicyBotulinum Toxin Prior Authorization Policy - Medicare Part B
    Policy CodePolicy ORPTCNEU030.0826
    Change TypeNo material clinical or coverage changes
    Effective DateOctober 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateNot specified
    Key ActionSubmit the diagnosis and billing information required by the applicable CMS LCD and Billing and Coding article.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearAuthorization duration
    12 weeksMinimum administration interval
    6Products with FDA-approved indications
    15+FDA-approved indication categories
    L35172Applicable Medicare guideline

    Coverage Criteria

    FDA-Approved Indications

    Covered when the requested product and indication correspond to an FDA-approved indication and applicable CMS medical necessity criteria are met.

    FDA-approved covered use: The requested botulinum toxin product is being used for an FDA-approved indication listed in this policy, and the request meets the applicable CMS LCD criteria.

    Botulinum toxin products are not interchangeable; approved indications differ by product.

    Off-Label Indications

    Off-label requests require individualized medical necessity review.

    Off-label evaluation: The proposed indication is listed in AHFS, Drugdex, or NCCN; the prescriber provides medical rationale; relevant formulary alternatives and published evidence are considered; and the use is not determined experimental or investigational.

    Coverage decisions are made through individualized determinations of medical necessity and the experimental or investigational character of the treatment.

    Medical Necessity Diagnosis-Code Requirement

    Botulinum toxin therapy may be considered medically necessary when billed with a diagnosis code listed in the policy's medical-necessity diagnosis tables.

    Listed diagnosis requirement: The botulinum toxin medication HCPCS code and diagnosis-code combination must appear in the medical-necessity diagnosis tables.Diagnosis code listed in the policy tables

    If the diagnosis code is not listed, the claim is considered not medically necessary.

    FDA-Approved Indications for Covered Drugs

    Covered drugs are evaluated against FDA-approved indications.

    FDA indication requirement: The covered botulinum toxin drug must be used for an FDA-approved indication identified by the policy or its referenced indication table.FDA-approved indication

    Refer to the FDA Approved Indications for Covered Drugs.

    Cosmetic procedures are excluded under Medicare. Botulinum toxin therapy must otherwise be used according to the applicable FDA-approved indication and coverage requirements.

    Coverage is subject to the FDA-approved indication and product-specific labeling for the requested botulinum toxin product. Limitations include, among others, no established safety or effectiveness for episodic migraine prophylaxis, treatment of fixed-contracture spasticity, hyperhidrosis outside the axilla, and axillary hyperhidrosis in pediatric patients under age 18.

    Botulinum toxin therapy billed for glabellar lines with ICD-10-CM L98.8 is excluded from coverage.

    An unlisted procedure code submitted for a non-covered service addressed by this policy will be denied as not covered. Unlisted codes for potentially covered services are reviewed at the claim level for medical necessity, correct coding, and pricing.

    An off-label use determined to be experimental or investigational is not covered. Off-label requests are evaluated individually, including the available evidence, medical rationale, recognized compendia support, and relevant formulary alternatives.

    Botulinum toxin therapy may be considered medically necessary only when the billed diagnosis code is included in the policy’s medical-necessity diagnosis tables. If the diagnosis code is not listed, the claim is considered not medically necessary.

    Initial Therapy Criteria

    Initial Botulinum Toxin Therapy

    Initial coverage follows applicable CMS criteria and the FDA-approved indication for the requested product.

    Initial therapy requirements

    • The request meets the applicable CMS medical necessity criteria.
    • The requested botulinum toxin product is being used for an FDA-approved indication listed in the policy.

      Botulinum toxin products are not interchangeable; approved indications differ by product.

    Continuation and Reauthorization Criteria

    Continuation Authorization Duration

    Reauthorization is approved for one year.

    Reauthorization period: Continuation authorization, when approved, is issued for one year.1 year

    The policy does not provide additional continuation-response criteria in this section.

    Coding and Diagnosis Requirements

    Covered CPT procedure codesCPTCovered
    31513Laryngoscopy, indirect; with vocal cord injection
    31570Laryngoscopy, direct, with injection into vocal cord(s), therapeutic
    43201Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance
    43236Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance
    46505Chemodenervation of internal anal sphincter
    52287Cystourethroscopy, with injection(s) for chemodenervation of the bladder
    64611Chemodenervation of parotid and submandibular salivary glands, bilateral
    64612Chemodenervation of muscle(s); muscle(s) innervated by facial nerve, unilateral (eg, for blepharospasm, hemifacial spasm)
    64615Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)
    64616Chemodenervation of muscle(s); neck muscle(s), excluding muscles of the larynx, unilateral (eg, for cervical dystonia, spasmodic torticollis)
    Additional covered CPT and HCPCS codesmixedCovered
    64617Chemodenervation of muscle(s); larynx, unilateral, percutaneous (eg, for spasmodic dysphonia), includes guidance by needle electromyography, when performed
    64640Destruction by neurolytic agent; other peripheral nerve or branch
    64642Chemodenervation of one extremity; 1-4 muscle(s)
    64643Chemodenervation of one extremity; each additional extremity, 1-4 muscle(s)
    64644Chemodenervation of one extremity; 5 or more muscles
    64645Chemodenervation of one extremity; each additional extremity, 5 or more muscles
    64646Chemodenervation of trunk muscle(s); 1-5 muscle(s)
    64647Chemodenervation of trunk muscle(s); 6 or more muscles
    64650Chemodenervation of eccrine glands; both axillae
    64653Chemodenervation of eccrine glands; other area(s) (eg, scalp, face, neck), per day
    1–10 of 18
    1/2
    Unlisted codesCPT
    43499Unlisted procedure, esophagus
    64999Unlisted procedure, nervous system
    Non-covered Diagnosis CodesICD-10Not Covered
    L98.8Glabellar lines
    Medical Necessary Diagnosis Codes — medication HCPCS J0585, J0586; diagnosis F64.0mixedCovered
    J0585
    J0586
    F64.0
    Medical Necessary Diagnosis Codes — medication HCPCS J0585, J0586; diagnoses F64.1, F64.8mixedCovered
    J0585
    J0586
    F64.1
    F64.8
    Medical Necessary Diagnosis Codes — migraine and related diagnosesmixedCovered
    J0585
    F64.9
    G43.001
    G43.009
    G43.011
    G43.019
    G43.101
    G43.109
    G43.111
    G43.119
    1–10 of 46
    1/5
    Medical Necessary Diagnosis Codes — neuromuscular, spasticity, dystonia, cerebral palsy, paralysis, and post-stroke diagnosesmixedCovered
    J0585
    J0586
    J0588
    G04.1
    G11.4
    G24.02
    G24.09
    G24.1
    G24.2
    G25.0
    1–10 of 126
    1/13
    Medical Necessary Diagnosis Codes — ophthalmologic, ocular-motor, sweating, and urinary diagnosesmixedCovered
    J0585
    H49.01
    H49.02
    H49.03
    H49.11
    H49.12
    H49.13
    H49.21
    H49.22
    H49.23
    1–10 of 106
    1/11
    Medical Necessary Diagnosis Codes — medication HCPCS J0584; diagnoses N30.10, N30.11, R39.89mixedCovered
    J0584
    N30.10
    N30.11
    R39.89
    Medical Necessary Diagnosis Codes — medication HCPCS J0585; urinary diagnosesmixedCovered
    J0585
    N32.81
    N39.41
    N39.42
    N39.43
    N39.44
    N39.45
    N39.46
    N39.490
    N39.491
    1–10 of 12
    1/2
    Medical Necessary Diagnosis Codes — urinary and facial-nerve diagnosesICD-10Covered
    N31.1
    N31.2
    N31.8
    N31.9
    G51.2
    G51.31
    G51.32
    G51.33
    G51.4
    G51.8
    Medical Necessary Diagnosis Codes — gastrointestinal, laryngeal, esophageal, dystonia, salivary, and eyelid diagnosesmixedCovered
    K60.0
    K60.1
    K60.2
    K60.30
    K60.311
    K60.312
    K60.313
    J0585
    K60.412
    K60.413
    1–10 of 51
    1/6
    Administration interval
    Minimum intervalBotulinum toxin should not be administered more frequently than every 12 weeks.
    Frequency standardThe 12-week interval is the general administration standard for botulinum toxin therapy.
    Coverage consequenceTreatment administered more frequently than every 12 weeks may be denied.

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    One-Year Authorization Period

    Initial authorization and reauthorization will be approved for a one-year period.

    • Applies to both initial authorization and reauthorization.
    Prior Authorization

    Recently FDA-Approved Indications

    Requests for indications approved by the FDA within the previous six months may not yet have been reviewed by the health plan for safety, effectiveness, or inclusion in this policy. Submit these requests through the New Drug and/or Indication Awaiting P&T Review prior authorization pathway.

    • Use ORPTCOPS047: New Drug and/or Indication Awaiting P&T Review; Prior Authorization Request.
    Prior Authorization

    Unlisted Procedure Prior Authorization

    Clinical Background

    Botulinum toxins are presynaptic neuromuscular blocking agents that prevent the release of acetylcholine from nerve endings. This produces localized chemical denervation and selective, temporary weakening of targeted muscles. Because botulinum toxin products are pharmacologically and clinically distinct and are not interchangeable, their FDA-approved indications and applicable coverage limitations differ by product.

    Definitions

    Botulinum toxin
    Drug classBotulinum toxins are neurotoxins and potent presynaptic neuromuscular blocking agents.
    MechanismThey prevent the release of acetylcholine from nerve endings, producing chemical denervation of the injected muscle.
    Clinical effectThe resulting local paresis or paralysis selectively weakens targeted muscles and is temporary as reinnervation returns after several weeks.
    Off-label indication
    DefinitionAn off-label indication is a use that is not FDA approved for the requested product and indication.
    Recognized sourcesFor coverage evaluation, the proposed indication must be listed in the American Hospital Formulary System (AHFS), Drugdex, or the National Comprehensive Cancer Network (NCCN).
    Policy Summary
    PayerProvidence Health Plan
    PolicyBotulinum Toxin Prior Authorization Policy - Medicare Part B
    Policy CodePolicy ORPTCNEU030.0826
    Change TypeNo material clinical or coverage changes
    Effective DateOctober 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateNot specified
    Key ActionSubmit the diagnosis and billing information required by the applicable CMS LCD and Billing and Coding article.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation and Reauthorization CriteriaCoding and Diagnosis RequirementsAuthorization, Documentation, and Denial RisksClinical BackgroundDefinitions

    Prior authorization is required when an unlisted code is billed for services addressed in this policy.

    • 43499 — Unlisted procedure, esophagus
    • 64999 — Unlisted procedure, nervous system
    Billing Rule

    Unlisted-Code Authorization Recommendation

    All unlisted codes are reviewed at the claim level for medical necessity, correct coding, and pricing. For potentially covered services addressed in this policy, prior authorization is recommended to support payment review.

    • Code-list inclusion or omission does not guarantee reimbursement or coverage.
    • Provider contracts, member benefits, eligibility, and utilization audit requirements may also apply.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: billing_rule

    Prior Authorization

    Prior Authorization for Unlisted Services

    Obtain prior authorization for potentially covered services addressed in this policy when submitted with an unlisted code, preferably before the service is performed, to reduce the risk of a post-service denial.

    • All unlisted codes remain subject to claim-level review for medical necessity, correct coding, and pricing.
    Denial Risk

    Off-Label Indication: Evidence and Rationale Required

    An off-label indication must be listed in the American Hospital Formulary Service (AHFS), Drugdex, or National Comprehensive Cancer Network (NCCN), and the request must include the prescriber’s medical rationale and supporting published evidence-based research. Without sufficient evidence or rationale, the request may be denied or determined experimental/investigational.

    • Coverage is based on an individualized determination of medical necessity and the experimental or investigational character of the treatment.
    • Include the proposed indication, prescriber rationale, and relevant evidence.
    Denial Risk

    Cosmetic Use Excluded

    Cosmetic botulinum toxin procedures are excluded from Medicare coverage.

    • CMS recommends botulinum therapy be used according to FDA-approved indications, except that cosmetic procedures are excluded under Medicare.
    Denial Risk

    Frequency and Safety Contraindications

    Botulinum toxin generally should not be administered more frequently than every 12 weeks and should not be used when the patient has a hypersensitivity or contraindication to botulinum toxin therapy.

    • Do not administer more frequently than every 12 weeks unless otherwise supported by applicable criteria.
    • Do not use in patients with hypersensitivity or contraindication, severe clotting disorders, or infection at the injection site.
    • Botulinum toxin products are not considered interchangeable.
    Denial Risk

    Unlisted Code for Non-Covered Service

    An unlisted code submitted for a non-covered service addressed in this policy will be denied as not covered.

    • Review the applicable non-covered-service list before billing.
    Denial Risk

    Glabellar Lines Excluded

    Glabellar lines are excluded from coverage when billed with ICD-10-CM code L98.8.

    • ICD-10-CM L98.8 — Glabellar lines: excluded from coverage.
    Denial Risk

    Diagnosis Code Must Be Listed

    Botulinum toxin therapy may be considered medically necessary only when billed with a diagnosis code listed in the policy’s medically necessary diagnosis-code tables. If the diagnosis code is absent from those tables, the claim is considered not medically necessary.

    • Confirm that the billed diagnosis appears in the applicable policy diagnosis-code table before submission.
    Denial Risk

    Policy Denial Rule for Unlisted Codes

    If an unlisted code is submitted for a service that is not covered under this policy, the claim will be denied as not covered rather than being treated as covered solely because the code is unlisted.

    • Unlisted-code review does not create coverage for an otherwise non-covered service.
    Billing Rule

    NCCI and MUE Edits Apply

    CMS National Correct Coding Initiative (NCCI) procedure-to-procedure bundling edits and medically unlikely edits (MUEs) continue to apply to applicable HCPCS and CPT codes.

    • This policy does not take precedence over NCCI edits or MUEs.
    • Follow CMS coding guidelines and applicable code combinations, including daily maximum edits.
    Clinical documentationThe prescriber must provide medical rationale; relevant formulary alternatives and available published evidence-based research are evaluated.
    Coverage limitationCoverage is determined individually, including whether the proposed use is experimental or investigational; an experimental or investigational use is not covered.